In Brief: Diatide
This article was originally published in The Gray Sheet
Diatide: Medical imaging agent manufacturer completes enrollment of 269 patients in a Phase III pivotal trial of its P829 injectable imaging product for detection and localization of lung cancer, the firm reports Dec. 29. Diatide plans to submit in the second quarter a new drug application for P829, which is comprised of a small-molecule, synthetic peptide and a molecule of technetium-99m. A conventional gamma camera is used to detect the technetium-99m molecule after the peptide in the agent binds to the somatostatin receptor, which is a growth hormone present in some cancers, the firm explains. Nycomed licenses and distributes P829 in Europe, South Africa and certain countries in the Middle East...
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.